Regeneron Pharmaceuticals (NASDAQ:REGN) announced that the U.S. FDA has extended the target action dates for two regulatory ...

The hits just keep on coming for Regeneron’s Eylea franchise. | The FDA has extended its target action dates for two ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® ...

Inspection at Novo Nordisk unit Catalent delays action to Q4 2025, but investors keep faith in Eylea's outlook.

Regeneron Pharmaceuticals, Inc. (REGN) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has extended ...

Regeneron (REGN) stock in focus as the company surpasses Street's Q2 projections with strong growth in high-dose Eylea, Dupixent, and Libtayo sales. Read more here.

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Regeneron plans to submit a supplemental biologics license application (sBLA) for Eylea HD for every four-week dosing and retinal vein occlusion in the first quarter of 2025 to potentially ...

Regeneron books full U.S. Eylea sales, and 80% of its Eylea-related revenue comes from the U.S. Blockbuster immunology drug Dupixent so far generates 80% of its sales in the U.S., and Regeneron is ...

(Reuters) -Regeneron Pharmaceuticals Inc's first-quarter sales of blockbuster eye drug Eylea came in below Wall Street targets on Thursday as competition heated up, dragging the company's shares ...

Humana is right behind the federal government in suing Regeneron for allegedly inflating its macular degeneration drug, Eylea, and using a "sham" charity to pay out kickbacks to cover cost-sharing ...

Investors recognizing that Regeneron's (REGN 2.18%) and Bayer's (BAYR.Y 1.78%) Eylea enjoys all three of these characteristics have caused Regeneron's shares to more than double in the past year.